That's the encouraging news from scientists at the Scripps Research Institute in California, who report their findings in issue 22 of the international edition of the journal Angewandte Chemie.

Advertisement

Infection causes inflammation and possible organ failure
Sepsis, also known as septic shock and systemic inflammatory response syndrome, is a severe illness caused by overwhelming infection of the bloodstream by toxin-producing bacteria.

"It occurs in two of every 100 hospital admissions, and is caused by bacterial infection that can originate anywhere in the body," according to the National Institutes of Health.

It begins with an infection. The immune system is then activated and that sets off a cascade of events, such as uncontrolled inflammation and activation of the blood coagulation system.

Next, there can be multiple organ failures, from which many sepsis patients eventually die.

Doctors have been successful at reducing the percentage of people who die from sepsis, which is generally treated with antibiotics to quell the infection. However, overall deaths are up as the incidence of sepsis has risen.

Neutralising the endotoxins
In the past, other researchers have tried to protect against sepsis by infusing antibodies to target endotoxins.

These are dangerous chemical components of certain bacteria that can cause the immune system to overreact and release lethal amounts of inflammatory chemicals, such as tumour necrosis factor alpha, or TNF-alpha. However, the results haven't been encouraging.

The new Scripps vaccine takes a more active approach. It aims to neutralise the endotoxins and prevent the overreaction of the immune system.

Reducing body's inflammation response
The researchers vaccinated mice after giving them a sub-lethal dose of lipid A, a component of endotoxins, says Paul Wentworth Jr, an associate professor of chemistry at Scripps and a co-author of the study.

The vaccine produced a nearly 95 percent reduction in the production of TNF-alpha, a good indication that the vaccine controlled the body's response to infection.

"Normally the body makes TNF-alpha," Wentworth says. However, in the case of sepsis, its production can spiral out of control. "The TNF-alpha is a marker for the body's over-response to the bacterial endotoxins," he says.

"We think the vaccine is working in two ways," Wentworth adds. "It is binding to the lipid A and neutralising its activity. And it could also be generating antibodies that catalyse the destruction of lipid A molecules."

Human trials on the horizon
Wentworth says the study, while promising, is preliminary. If continuing studies show positive results, he says the researchers hope that human trials could begin in the next five years or so.

It would likely take a decade before the vaccine is on the market, he says. – (HealthScout News)

Rate this article Poor 1 2 3 4 5 Excellent

JOBS

Operations Manager R20,000-25,000 Per Month Cost To Company Incl Benefits Gauteng - East Rand Financial Accountant: CA(SA) R400,000-500,000 Per Annum Cost To Company Gauteng - Johannesburg Key Account Manager Gauteng Java Developer-CT Western Cape - Cape Town Java Developer-Jozi Gauteng Account Manager R460,000-540,000 Per Annum Cost To Company Plus Benefits Gauteng Account Manager R460,000-540,000 Per Annum Market Related Plus Benefits South Africa Case Manager R210,000-220,000 Per Annum Negotiable Gauteng - Pretoria Find more jobs Register your CV Post a job